Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
12.50
+0.25 (2.04%)
At close: Dec 5, 2025
-53.70%
Market Cap17.26M
Revenue (ttm)n/a
Net Income (ttm)-4.44M
Shares Out138.07M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume154,413
Average Volume164,924
Open12.25
Previous Close12.25
Day's Range12.18 - 13.00
52-Week Range9.50 - 29.00
Beta-0.87
RSI33.51
Earnings DateMar 20, 2026

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

Full Year 2025 Sareum Holdings PLC Live Presentation Transcript

Full Year 2025 Sareum Holdings PLC Live Presentation Transcript

4 weeks ago - GuruFocus